Glenmark Pharmaceuticals Inc, USA has launched Calcium Gluconate Injection USP in three presentations for the US healthcare market, expanding the company’s portfolio of injectable medicines supplied to hospitals and healthcare institutions. The newly launched products include 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, both with a concentration of 100 mg/mL, along with a 10,000 mg/100 mL pharmacy bulk package at the same concentration.
Glenmark said its Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Calcium Gluconate Injection from Fresenius Kabi USA, LLC. The reference product is listed under NDA 208418. According to IQVIA sales data for the 12-month period ending June 2026, the US market for the three presentations recorded annual sales of approximately $69.9 million.
The launch is part of Glenmark’s strategy to strengthen its US injectable medicines business and expand its hospital-focused portfolio. The company said the addition of calcium gluconate injection supports its efforts to develop a broader range of products for institutional healthcare requirements.
Marc Kikuchi, President and Business Head, North America, Glenmark, said the launch represents another step in expanding the company’s injectable business in the US. He said the company is focused on developing a differentiated and sustainable injectables portfolio that addresses institutional requirements, strengthens supply resilience and increases Glenmark’s presence across the US healthcare system.
The launch adds to Glenmark’s growing range of pharmaceutical products in the US market. The company has been expanding its portfolio across branded, innovative, generic and consumer healthcare products, with key focus areas including respiratory care, dermatology and oncology.
Glenmark Pharmaceuticals Ltd is a research-led pharmaceutical company focused on innovation and access to medicines. The company operates 11 manufacturing facilities across four continents and has six research and development centres.Its commercial operations extend across more than 80 countries. Glenmark’s portfolio covers branded medicines, innovative products, generics and consumer healthcare offerings.
The company has established operations across several therapeutic areas and continues to invest in product development and manufacturing capabilities. Its US business includes a portfolio of medicines serving institutional and other healthcare needs. The introduction of Calcium Gluconate Injection USP strengthens Glenmark’s presence in the US hospital segment while adding another injectable product to its commercial portfolio. Glenmark said the launch reflects its continued focus on expanding its US pharmaceutical business through products that address established healthcare requirements and support the company’s long-term growth strategy.
